Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2017-03-14, 10:25:37 | version 1.49.03
A faster and more precise diagnoses using molecular biologi- cal approaches or new opportunities for recovery through regenerative medicine and individualized therapy approaches – one example is the coordinated interplay between a (“biologized”) implant and its physiological environment – are scientiic trends that are becoming more important because of the increase in life expectancy. Hence, drug eficacy has to be improved, for example by optimizing formulations and targeted release of active ingredients at the sites where they are needed. Fraunhofer IGB is developing solutions in these research areas. The aim is to improve medical care for patients and simultaneously reduce healthcare costs. Another focus is the development of three-dimensional in vitro organoid models derived from human tissues; preclinical research has already produced conclusions about effects and side effects of po- tential drug candidates and thus animal experiments are no longer required. We take increased health awareness into account by using new extraction, preparation and stabilization processes that minimize damage to food products and can also be used for cosmetics. Networking and cooperation With our expertise, we contribute to the offerings of the Fraunhofer Group for Life Sciences, facilitating a scope of ac- tivity ranging from the development of medicines to screening for active agents to the production of test samples. As a part- ner of the Fraunhofer Food Chain Management Alliance, we make a contribution to healthcare through the development of physical hygienization processes that protect the properties of products. In addition, we are networked in the Fraunhofer Big Data and Generative Manufacturing Alliances.